- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00911651
Study to Assess the Effect of Salbutamol and Ipratropium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients
Open, Randomized, Two-Way Crossover, Pilot Study to Assess the Effect of Salbutamol in Comparison With Ipratropium Bromide on Central and Peripheral Airway Dimensions in COPD Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Salbutamol (VentolinTM) is a short acting beta agonist (SABA) which is used to treat wheezing, dyspnea and breathing difficulties caused by asthma and COPD. Further, it is also used to prevent bronchospasm during exercise.
Ipratropium bromide (Atrovent® HFA) is a short acting anticholinergic bronchodilator (short acting muscarinic antagonist (SAMA)) that improves lung function, dyspnea, exercise tolerance and health-related quality of life in patients with COPD. Studies have also shown that ipratropium bromide might reduce COPD exacerbations and related hospitalisations because the extended bronchodilatation might reduce infection rates by improving clearance of respiratory secretions.
In this open, randomized, two-way crossover, pilot study the effect of salbutamol in patients with moderate and severe COPD will be examined in comparison with the effects of ipratropium bromide. These patients will receive 400 µg salbutamol and 80 µg ipratropium bromide in a randomized crossover design.
The objectives of this study are to assess the effect of salbutamol in comparison with ipratropium bromide on the geometry of central and peripheral airways and to correlate spirometric indices (as Forced Expiratory Volume in one second (FEV1) and Tiffeneau index) with the Computational Fluid Dynamics (CFD) based calculated airway volumes and resistances for both compounds.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Antwerp, Belgium, 2650
- Antwerp University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients with documented COPD based on the following criteria:
- Smoking history of at least 10 pack-years.
- Decreased Tiffeneau index (FEV1/(F)VC < 0.70).
- Patients aged ≥ 40 years.
- Patients should present moderate to severe COPD with an FEV1 between 30 and 80% of predicted (GOLD 2 and 3).
- Patients should be treated according to GOLD guidelines.
- Able to inhale study drug.
- Maintained on stable respiratory medications for 6 weeks prior to visit 1.
- Able to perform lung function tests.
- Able to follow study procedures.
Exclusion Criteria:
- Patients who are allergic to salbutamol, ipratropium bromide or to another element of the product.
- Patients allergic to sojalecithin and products on the basis of soja and peanut.
- Patients who have or ever had glaucoma.
- Patients with urinary problems, prostate hyperplasy or bladder-neck obstruction. Patients whose symptoms are controlled on treatment may be included.
- Patients with a recent history (i.e. six months or less) of myocardial infarction.
- Patients with any unstable or life threatening cardiac arrhythmia.
- Patients with severe kidney insufficiency (creatinine clearance ≤50 ml/min)a.
- Patients below the age of 40.
- Patients who are pregnant or are breast-feeding.
- Patients who are treated with other anticholinergic medications, that cannot be stopped during the study period.
- A respiratory infection or exacerbation of COPD in the four weeks prior to screening.
- Significant alcohol or drug abuse within the past 12 months.
- Participation in another trial with an investigational drug within one month or six half lives (whichever is greater) prior to screening visit.
- Known active tuberculosis.
- A history of asthma, cystic fibrosis, central bronchiectasis, interstitial lung disease or pulmonary thromboembolic disease.
- A history of thoracotomy with pulmonary resection.
- Active or untreated malignancy.
- Use of oral corticosteroid medication at unstable doses (i.e. less than six weeks on a stable dose) or at doses ≥ 10 mg/day.
a Cockroft's formulae should be applied: in male: creatinine clearance = (140-age) x weight / 72 x creatininemia in female: creatinine clearance = 0.85 x (140-age) x weight / 72 x creatininemia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: salbutamol
6 patients with moderate (GOLD 2) and severe (GOLD 3) COPD
|
400 µg inhalation once
Other Names:
|
Active Comparator: ipratropium bromide
COPD patients GOLD stage II and III
|
80 µg inhalation once
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary objective of this study is to assess the effect of a single dose of salbutamol in comparison with ipratropium bromide on central and peripheral small airways with high-resolution/multislice CT scan imaging technique.
Time Frame: 1 month
|
1 month
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The secondary objectives are to evaluate effects on spirometric indices to correlate these with the CFD based calculated airway volumes and resistances for both compounds and to evaluate the safety of the products.
Time Frame: 1 month
|
1 month
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Wilfried A De Backer, MD PhD, University Hospital, Antwerp
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Antagonists
- Cholinergic Agents
- Adrenergic Agonists
- Anticonvulsants
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Reproductive Control Agents
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
- Tocolytic Agents
- Albuterol
- Bromides
- Ipratropium
Other Study ID Numbers
- PML_DOC_0801
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COPD
-
University Medical Center GroningenCompleted
-
Istituto Nazionale di Ricovero e Cura per AnzianiRecruiting
-
Bio-Sensing Solutions S.L. (DyCare)Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau; Centre...Not yet recruiting
-
Sir Run Run Shaw HospitalRecruiting
-
University Hospital, BrestRecruiting
-
The First Affiliated Hospital of Guangzhou Medical...Recruiting
-
Association des Réseaux BronchioliteLaboratoire Système et Matériaux pour la Mécatronique (SYMME)Recruiting
-
Baylor Research InstituteNot yet recruiting
-
Polytechnic Institute of PortoNippon Gases PortugalRecruiting
Clinical Trials on Salbutamol
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Canisius-Wilhelmina HospitalRecruitingAsthma in Children | Agents, Anti AsthmaticNetherlands
-
Vastra Gotaland RegionEnrolling by invitationMusculoskeletal Diseases | Neuromuscular Diseases | Centronuclear Myopathy | Nemaline Myopathy | Congenital Myopathy | Myosin Storage MyopathySweden
-
Chiesi Farmaceutici S.p.A.CompletedBronchial AsthmaSpain, Italy, Russian Federation, Ukraine
-
University of Wisconsin, MadisonEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedObesity | Pregnancy | PreeclampsiaUnited States
-
Shanghai Ninth People's Hospital Affiliated to...UnknownAdenoid Cystic CarcinomaChina
-
Boehringer IngelheimCompletedPulmonary Disease, Chronic Obstructive
-
Research in Real-Life LtdTeva Branded Pharmaceutical Products R&D, Inc.CompletedAsthmaUnited Kingdom
-
The Hospital for Sick ChildrenUniversity Health Network, TorontoRecruiting